Neurocrine Biosciences | NBIX - Zinsaufwendungen Für Schuld

Aktienkurs
128.89
Täglich Wechseln
-2.75 -2.09%
Monatlich
-0.50%
Jährlich
41.84%
Q2 Prognose
125.37




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
ALKERMES USD 12.28M 7.63M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Cytokinetics USD 30.33M 4.01M 2025-12
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 255M 1000K 2025-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 711M 59M 2025-12
Prothena USD 2.62M 350M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Repligen USD 5.5M 81K 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xoma USD 3.4M 150K 2024-06